JP2024546605A5 - - Google Patents
Info
- Publication number
- JP2024546605A5 JP2024546605A5 JP2024531205A JP2024531205A JP2024546605A5 JP 2024546605 A5 JP2024546605 A5 JP 2024546605A5 JP 2024531205 A JP2024531205 A JP 2024531205A JP 2024531205 A JP2024531205 A JP 2024531205A JP 2024546605 A5 JP2024546605 A5 JP 2024546605A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- product according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265441P | 2021-12-15 | 2021-12-15 | |
| US63/265,441 | 2021-12-15 | ||
| PCT/US2022/081592 WO2023114871A1 (en) | 2021-12-15 | 2022-12-14 | Use of combination therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546605A JP2024546605A (ja) | 2024-12-26 |
| JP2024546605A5 true JP2024546605A5 (cg-RX-API-DMAC7.html) | 2026-01-15 |
Family
ID=86773654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531205A Pending JP2024546605A (ja) | 2021-12-15 | 2022-12-14 | がんを治療するための併用療法の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325397A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4447973A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546605A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240119096A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119136807A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022409798A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242265A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007260A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202333675A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023114871A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2025123287A1 (en) * | 2023-12-14 | 2025-06-19 | Remegen Co., Ltd. | Methods of treating breast cancer using anti-her2 antibody-drug conjugates and other therapeutic agents |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025231223A1 (en) * | 2024-05-02 | 2025-11-06 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2022
- 2022-12-14 MX MX2024007260A patent/MX2024007260A/es unknown
- 2022-12-14 EP EP22908677.2A patent/EP4447973A4/en active Pending
- 2022-12-14 CN CN202280082158.0A patent/CN119136807A/zh active Pending
- 2022-12-14 CA CA3242265A patent/CA3242265A1/en active Pending
- 2022-12-14 AU AU2022409798A patent/AU2022409798A1/en active Pending
- 2022-12-14 KR KR1020247022101A patent/KR20240119096A/ko active Pending
- 2022-12-14 JP JP2024531205A patent/JP2024546605A/ja active Pending
- 2022-12-14 WO PCT/US2022/081592 patent/WO2023114871A1/en not_active Ceased
- 2022-12-15 TW TW111148297A patent/TW202333675A/zh unknown
-
2024
- 2024-06-14 US US18/743,564 patent/US20240325397A1/en active Pending